Heron Neutron Lists on the Stock Market, Opening New Chapter in Cancer Treatment

Source: Economic Daily News (Taiwan)

 

Heron Neutron Medical Corp. (Heron), a leading brand in precision cancer therapy guided by Fubon Securities, officially began trading on the stock market on September 15, 2025, with an offering price of NT$600 per share, injecting new momentum into Taiwan’s capital markets. The company has deep expertise in Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT), and its advanced technology enables precise treatment of cancer cells while minimizing impact on healthy cells, offering significant benefits for patients.

 

Following its listing, Heron plans to leverage capital market resources to continue strengthening its technological research and international market expansion, with the goal of becoming a global leader in AB-BNCT-based precision cancer treatment.

 

At the listing ceremony, Fubon Securities General Manager Kuo Yong-yi stated that Heron has demonstrated exceptional integration capabilities in the AB-BNCT field and successfully bridged the highly challenging domains of nuclear physics, engineering, and pharmaceuticals to build a comprehensive cancer precision treatment system.

 

Heron has obtained the medical device approval for its AB-BNCT system, symbolizing a significant milestone in Taiwan’s autonomous development of advanced radiation medical technology and opening a new chapter for the domestic medical technology industry.

 

Heron’s General Manager Leo Shen said that the company has achieved what many biotech firms find difficult: it has invested substantial capital and resources to address equipment deployment, drug development, and clinical trials, and has completed system verification and drug testing, demonstrating a technological lead in AB-BNCT development. Today’s stock listing is an important milestone for the company, which will continue to create value for customers, employees, and investors.